The antibiotic polymyxin B impairs the interactions between Shiga toxins and human neutrophils

Journal of Immunology

Volumn 196, Issue 3, 2016, Pages 1177-1185

  Carnicelli, Domenica ^a   Arfilli, Valentina ^a   Ricci, Francesca ^b   Velati, Claudio ^b   Tazzari, Pier Luigi ^b   Brigotti, Maurizio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GELONIN; GLOBOTRIAOSYLCERAMIDE; INTERLEUKIN 8; POLYMYXIN B; SHIGA TOXIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG EFFICACY; ENZYME ACTIVITY; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; MALE; MOLECULAR INTERACTION; MOUSE; NEUTROPHIL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAJI CELL LINE; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; ANIMAL; DRUG EFFECTS; FLOW CYTOMETRY; HEMOLYTIC-UREMIC SYNDROME; IMMUNOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; FLOW CYTOMETRY; HEMOLYTIC-UREMIC SYNDROME; HUMANS; MICE; NEUTROPHILS; POLYMYXIN B; SHIGA TOXIN;

EID: 84957637619     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1500671     Document Type: Article

References (56)

1. Griffin, P. M., and R. V. Tauxe. 1991. The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. Coli, and the associated hemolytic uremic syndrome. Epidemiol. Rev. 13: 60-98.
2. Tarr, P. I., C. A. Gordon, and W. L. Chandler. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 365: 1073-1086.
3. Trompeter, R. S., R. Schwartz, C. Chantler, M. J. Dillon, G. B. Haycock, R. Kay, and T. M. Barratt. 1983. Haemolytic-uraemic syndrome: an analysis of prognostic features. Arch. Dis. Child. 58: 101-105.
4. Würzner, R., M. Riedl, A. Rosales, and D. Orth-Höller. 2014. Treatment of enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome (eHUS). Semin. Thromb. Hemost. 40: 508-516.
5. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11: 450-479.
6. Friedrich, A. W., M. Bielaszewska, W. L. Zhang, M. Pulz, T. Kuczius, A. Ammon, and H. Karch. 2002. Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J. Infect. Dis. 185: 74-84.
7. Noris, M., and G. Remuzzi. 2005. Hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16: 1035-1050.
8. Ray, P. E., and X. H. Liu. 2001. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr. Nephrol. 16: 823-839.
9. Bauwens, A., J. Betz, I. Meisen, B. Kemper, H. Karch, and J. Müthing. 2013. Facing glycosphingolipid-Shiga toxin interaction: dire straits for endothelial cells of the human vasculature. Cell. Mol. Life Sci. 70: 425-457.
10. Endo, Y., K. Tsurugi, T. Yutsudo, Y. Takeda, T. Ogasawara, and K. Igarashi. 1988. Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur. J. Biochem. 171: 45-50.
11. Barbieri, L., P. Valbonesi, M. Brigotti, L. Montanaro, F. Stirpe, and S. Sperti. 1998. Shiga-like toxin I is a polynucleotide:adenosine glycosidase. Mol. Microbiol. 29: 661-662.
12. Brigotti, M., L. Barbieri, P. Valbonesi, F. Stirpe, L. Montanaro, and S. Sperti. 1998. A rapid and sensitive method to measure the enzymatic activity of ribosome-inactivating proteins. Nucleic Acids Res. 26: 4306-4307.
13. Brigotti, M., R. Alfieri, P. Sestili, M. Bonelli, P. G. Petronini, A. Guidarelli, L. Barbieri, F. Stirpe, and S. Sperti. 2002. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. FASEB J. 16: 365-372.
14. Brigotti, M., D. Carnicelli, E. Ravanelli, A. G. Vara, C. Martinelli, R. R. Alfieri, P. G. Petronini, and P. Sestili. 2007. Molecular damage and induction of proinflammatory cytokines in human endothelial cells exposed to Shiga toxin 1, Shiga toxin 2, and a-sarcin. Infect. Immun. 75: 2201-2207.
15. Matussek, A., J. Lauber, A. Bergau, W. Hansen, M. Rohde, K. E. Dittmar, M. Gunzer, M. Mengel, P. Gatzlaff, M. Hartmann, et al. 2003. Molecular and functional analysis of Shiga toxin-induced response patterns in human vascular endothelial cells. Blood 102: 1323-1332.
16. Arfilli, V., D. Carnicelli, L. Rocchi, F. Ricci, P. Pagliaro, P. L. Tazzari, and M. Brigotti. 2010. Shiga toxin 1 and ricin A chain bind to human polymorphonuclear leucocytes through a common receptor. Biochem. J. 432: 173-180.
17. Brigotti, M., D. Carnicelli, V. Arfilli, N. Tamassia, F. Borsetti, E. Fabbri, P. L. Tazzari, F. Ricci, P. Pagliaro, E. Spisni, and M. A. Cassatella. 2013. Identification of TLR4 as the receptor that recognizes Shiga toxins in human neutrophils. J. Immunol. 191: 4748-4758.
18. te Loo, D. M., L. A. Monnens, T. J. van Der Velden, M. A. Vermeer, F. Preyers, P. N. Demacker, L. P. van Den Heuvel, and V. W. van Hinsbergh. 2000. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. Blood 95: 3396-3402.
19. Brigotti, M. 2012. The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? Toxins (Basel) 4: 157-190.
20. Geelen, J. M., T. J. van der Velden, D. M. Te Loo, O. C. Boerman, L. P. van den Heuvel, and L. A. Monnens. 2007. Lack of specific binding of Shiga-like toxin (verocytotoxin) and non-specific interaction of Shiga-like toxin 2 antibody with human polymorphonuclear leucocytes. Nephrol. Dial. Transplant. 22: 749-755.
21. Brigotti, M., D. Carnicelli, E. Ravanelli, S. Barbieri, F. Ricci, A. Bontadini, A. E. Tozzi, G. Scavia, A. Caprioli, and P. L. Tazzari. 2008. Interactions between Shiga toxins and human polymorphonuclear leukocytes. J. Leukoc. Biol. 84: 1019-1027.
22. Brigotti, M., P. L. Tazzari, E. Ravanelli, D. Carnicelli, S. Barbieri, L. Rocchi, V. Arfilli, G. Scavia, F. Ricci, A. Bontadini, et al. 2010. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. J. Leukoc. Biol. 88: 201-210.
23. Griener, T. P., G. L. Mulvey, P. Marcato, and G. D. Armstrong. 2007. Differential binding of Shiga toxin 2 to human and murine neutrophils. J. Med. Microbiol. 56: 1423-1430.
24. Stahl, A. L., L. Sartz, A. Nelsson, Z. D. Békássy, and D. Karpman. 2009. Shiga toxin and lipopolysaccharide induce platelet-leukocyte aggregates and tissue factor release, a thrombotic mechanism in hemolytic uremic syndrome. PLoS One 4: e6990.
25. Tazzari, P. L., F. Ricci, D. Carnicelli, A. Caprioli, A. E. Tozzi, G. Rizzoni, R. Conte, and M. Brigotti. 2004. Flow cytometry detection of Shiga toxins in the blood from children with hemolytic uremic syndrome. Cytometry B Clin. Cytom. 61: 40-44.
26. Brigotti, M., D. Carnicelli, V. Arfilli, L. Rocchi, F. Ricci, P. Pagliaro, P. L. Tazzari, A. G. Vara, M. Amelia, F. Manoli, and S. Monti. 2011. Change in conformation with reduction of a-helix content causes loss of neutrophil binding activity in fully cytotoxic Shiga toxin 1. J. Biol. Chem. 286: 34514-34521.
27. Brigotti, M., P. L. Tazzari, E. Ravanelli, D. Carnicelli, L. Rocchi, V. Arfilli, G. Scavia, F. Minelli, F. Ricci, P. Pagliaro, et al. 2011. Clinical relevance of Shiga toxin concentrations in the blood of patients with hemolytic uremic syn-drome. Pediatr. Infect. Dis. J. 30: 486-490.
28. Caprioli, A., I. Luzzi, F. Rosmini, P. Pasquini, R. Cirrincione, A. Gianviti, M. C. Matteucci, and G. Rizzoni, The HUS Italian Study Group. 1992. Hemolytic-uremic syndrome and Vero cytotoxin-producing Escherichia coli infection in Italy. J. Infect. Dis. 166: 154-158.
29. Karmali, M. A., M. Petric, C. Lim, P. C. Fleming, G. S. Arbus, and H. Lior. 1985. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J. Infect. Dis. 151: 775-782.
30. Te Loo, D. M., V. W. van Hinsbergh, L. P. van den Heuvel, and L. A. Monnens. 2001. Detection of verocytotoxin bound to circulating polymorphonuclear leukocytes of patients with hemolytic uremic syndrome. J. Am. Soc. Nephrol. 12: 800-806.
31. Fernandez, G. C., S. A. Gomez, M. V. Ramos, L. V. Bentancor, R. J. Fernandez-Brando, V. I. Landoni, L. Lopez, F. Ramirez, M. Diaz, M. Alduncin, et al. 2007. The functional state of neutrophils correlates with the severity of renal dysfunction in children with hemolytic uremic syndrome. Pediatr. Res. 61: 123-128.
32. Coad, N. A., T. Marshall, B. Rowe, and C. M. Taylor. 1991. Changes in the postenteropathic form of the hemolytic uremic syndrome in children. Clin. Nephrol. 35: 10-16.
33. Milford, D. V., C. M. Taylor, B. Guttridge, S. M. Hall, B. Rowe, and H. Kleanthous. 1990. Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch. Dis. Child. 65: 716-721.
34. Walters, M. D., I. U. Matthei, R. Kay, M. J. Dillon, and T. M. Barratt. 1989. The polymorphonuclear leucocyte count in childhood haemolytic uraemic syndrome. Pediatr. Nephrol. 3: 130-134.
35. Brigotti, M., A. Caprioli, A. E. Tozzi, P. L. Tazzari, F. Ricci, R. Conte, D. Carnicelli, M. A. Procaccino, F. Minelli, A. V. Ferretti, et al. 2006. Shiga toxins present in the gut and in the polymorphonuclear leukocytes circulating in the blood of children with hemolytic-uremic syndrome. J. Clin. Microbiol. 44: 313-317.
36. Stahl, A. L., L. Sartz, and D. Karpman. 2011. Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Blood 117: 5503-5513.
37. Stahl, A. L., I. Arvidsson, K. E. Johansson, M. Chromek, J. Rebetz, S. Loos, A. C. Kristoffersson, Z. D. Békássy, M. Mörgelin, and D. Karpman. 2015. A novel mechanism of bacterial toxin transfer within host blood cell-derived microvesicles. PLoS Pathog. 11: e1004619.
38. Vaara, M. 2010. Polymyxins and their novel derivatives. Curr. Opin. Microbiol. 13: 574-581.
39. Morrison, D. C., and D. M. Jacobs. 1976. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry 13: 813-818.
40. Srimal, S., N. Surolia, S. Balasubramanian, and A. Surolia. 1996. Titration calo-rimetric studies to elucidate the specificity of the interactions of polymyxin B with lipopolysaccharides and lipid A. Biochem. J. 315: 679-686.
41. Bannatyne, R. M., N. M. Harnett, K. Y. Lee, and W. D. Biggar. 1977. Inhibition of the biologic effects of endotoxin on neutrophils by polymyxin B sulfate. J. Infect. Dis. 136: 469-474.
42. Danner, R. L., K. A. Joiner, M. Rubin, W. H. Patterson, N. Johnson, K. M. Ayers, and J. E. Parrillo. 1989. Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob. Agents Chemother. 33: 1428-1434.
43. Ryd, M., H. Alfredsson, L. Blomberg, A. Andersson, and A. A. Lindberg. 1989. Purification of Shiga toxin by a-D-galactose-(1 → 4)-b-D-galactose-(1 → 4)-b-D-glucose-(1 →) receptor ligand-based chromatography. FEBS Lett. 258: 320-322.
44. Zollman, T. M., P. R. Austin, P. E. Jablonski, and C. J. Hovde. 1994. Purification of recombinant Shiga-like toxin type I A1 fragment from Escherichia coli. Protein Expr. Purif. 5: 291-295.
45. Cassatella, M. A., R. Cappelli, V. Della Bianca, M. Grzeskowiak, S. Dusi, and G. Berton. 1988. Interferon-gamma activates human neutrophil oxygen metabolism and exocytosis. Immunology 63: 499-506.
46. van Setten, P. A., L. A. Monnens, R. G. Verstraten, L. P. van den Heuvel, and V. W. van Hinsbergh. 1996. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood 88: 174-183.
47. Macher, B. A., and J. C. Klock. 1980. Isolation and chemical characterization of neutral glycosphingolipids of human neutrophils. J. Biol. Chem. 255: 2092-2096.
48. Tesh, V. L., J. A. Burris, J. W. Owens, V. M. Gordon, E. A. Wadolkowski, A. D. O'Brien, and J. E. Samuel. 1993. Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect. Immun. 61: 3392-3402.
49. Sugatani, J., T. Igarashi, M. Munakata, Y. Komiyama, H. Takahashi, N. Komiyama, T. Maeda, T. Takeda, and M. Miwa. 2000. Activation of coagulation in C57BL/6 mice given verotoxin 2 (VT2) and the effect of co - Administration of LPS with VT2. Thromb. Res. 100: 61-72.
50. Zavascki, A. P., L. Z. Goldani, G. Cao, S. V. Superti, L. Lutz, A. L. Barth, F. Ramos, M. M. Boniatti, R. L. Nation, and J. Li. 2008. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin. Infect. Dis. 47: 1298-1304.
51. Louise, C. B., and T. G. Obrig. 1991. Shiga toxin - Associated hemolytic-uremic syndrome: combined cytotoxic effects of Shiga toxin, interleukin-1b, and tumor necrosis factor a on human vascular endothelial cells in vitro. Infect. Immun. 59: 4173-4179.
52. van de Kar, N. C., L. A. Monnens, M. A. Karmali, and V. W. van Hinsbergh. 1992. Tumor necrosis factor and interleukin-1 induce expression of the ver-ocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome. Blood 80: 2755-2764.
53. Justo, J. A., and J. A. Bosso. 2015. Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35: 28-33.
54. Vaara, M. 2013. Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68: 1213-1219.
55. 3 to antimicrobial and lipopolysaccharide binding activity. Chem. Pharm. Bull. (Tokyo) 57: 240-244.
56. Karpman, D., H. Connell, M. Svensson, F. Scheutz, P. Alm, and C. Svanborg. 1997. The role of lipopolysaccharide and Shiga-like toxin in a mouse model of Escherichia coli O157:H7 infection. J. Infect. Dis. 175: 611-620.